Zydus Cadila, Gilead Sciences ink non-exclusive licensing pact

17 Mar 2015 Evaluate

Zydus Cadila and Gilead Sciences, Inc. have signed a non-exclusive licensing agreement which will allow the manufacture of sofosbuvir and the fixed-dose combination of ledipasvir/ sofosbuvir for distribution in 91 countries including India. The breakthrough oral therapy, SoviHep which will provide succour to more than 10 mn patients who suffer from Hepatitis C in India has been launched by the Zydus group. The therapy will be marketed by the specialty division of the group, Zydus Heptiza.

Hepatitis C is an infectious disease affecting primarily the liver, caused by the Hepatitis C Virus (HCV). It spreads primarily through blood-to-blood contact associated with poorly sterilized medical equipment, and transfusions. An estimated 150-200 million people worldwide are infected with hepatitis C.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×